aTyr Pharma Inc (LIFE) Given Consensus Recommendation of “Hold” by Brokerages
aTyr Pharma Inc (NASDAQ:LIFE) has been given an average rating of “Hold” by the six brokerages that are currently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and two have issued a buy recommendation on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $3.33.
Several research firms have commented on LIFE. ValuEngine raised aTyr Pharma from a “strong sell” rating to a “sell” rating in a report on Wednesday, May 2nd. Zacks Investment Research raised aTyr Pharma from a “hold” rating to a “buy” rating and set a $3.00 target price on the stock in a report on Tuesday, April 3rd. Piper Jaffray Companies reissued an “overweight” rating and issued a $3.00 target price on shares of aTyr Pharma in a report on Monday, May 14th. Finally, Citigroup lowered aTyr Pharma from a “neutral” rating to a “sell” rating in a report on Monday, May 14th.
aTyr Pharma traded down $0.01, hitting $0.87, during trading on Tuesday, according to MarketBeat. 180,300 shares of the stock were exchanged, compared to its average volume of 401,587. The firm has a market cap of $27.14 million, a price-to-earnings ratio of -0.47 and a beta of 3.19. aTyr Pharma has a 1-year low of $0.80 and a 1-year high of $6.50. The company has a quick ratio of 6.90, a current ratio of 6.90 and a debt-to-equity ratio of 0.24.
In other aTyr Pharma news, Director Paul Schimmel purchased 150,000 shares of the firm’s stock in a transaction that occurred on Friday, May 18th. The shares were purchased at an average cost of $1.00 per share, for a total transaction of $150,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Ecor1 Capital Fund Qualified, sold 3,209,316 shares of aTyr Pharma stock in a transaction that occurred on Wednesday, May 16th. The shares were sold at an average price of $0.93, for a total value of $2,984,663.88. The disclosure for this sale can be found here. 25.00% of the stock is owned by insiders.
Several institutional investors have recently bought and sold shares of the stock. Sofinnova Ventures Inc purchased a new stake in shares of aTyr Pharma in the first quarter valued at approximately $4,945,000. Renaissance Technologies LLC boosted its position in aTyr Pharma by 143.2% during the fourth quarter. Renaissance Technologies LLC now owns 279,400 shares of the biotechnology company’s stock worth $978,000 after purchasing an additional 164,500 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in aTyr Pharma by 33.5% during the first quarter. Dimensional Fund Advisors LP now owns 114,449 shares of the biotechnology company’s stock worth $303,000 after purchasing an additional 28,699 shares in the last quarter. Finally, Deutsche Bank AG purchased a new stake in aTyr Pharma during the fourth quarter worth $199,000. Hedge funds and other institutional investors own 64.59% of the company’s stock.
About aTyr Pharma
aTyr Pharma, Inc, a clinical stage biotechnology company, engages in the discovery and development of medicines for the treatment of cancer and lung disease in the United States. The company's therapeutic candidate pipeline that includes ATYR1923 candidate, an agonist of the Resokine pathway that is in Phase I clinical trial designed to temper immune engagement in interstitial lung diseases; and ORCA program, a preclinical research stage program that targets immuno-oncology pathway using antibodies to enhance the immune response in tumor settings.
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.